CCL18 Rabbit Polyclonal Antibody

CCL18 (also known as PARC, DC-CK1, AMAC-1, or MIP-4) is an 8-kDa, primate-specific CC-chemokine consisting of 89 amino acids (with a 20-residue N-terminal signal peptide cleaved to yield the 69-aa mature form) that lacks a known rodent orthologue and whose receptor remains unidentified despite extensive research . Secreted predominantly by monocytes/macrophages and dendritic cells—especially M2 tumor-associated macrophages—CCL18 acts as a chemoattractant for lymphocytes and immature dendritic cells while also functioning as a neutral CCR3 antagonist and binding promiscuously to PITPNM3, GPR30, and CCR8. Constitutively present at high levels in human plasma, CCL18 contributes to physiological lymphocyte and DC homing and primary immune responses, yet its production is markedly up-regulated in numerous pathologies, including cancers (e.g., ovarian carcinoma) and inflammatory disorders of joints, lungs, and skin. Elevated circulating CCL18 correlates with adverse outcomes such as poor survival in ovarian cancer and increased mortality in idiopathic pulmonary fibrosis, highlighting its potential as a biomarker and therapeutic target.